Drug intelligence / Profile preview

macrogol 3350

Development stage
Unknown
Lead developer
Laboratorio Domínguez
Modality
Small Molecules
Administration
Oral
01

Overview

Barex is a brand of macrogol 3350 (polyethylene glycol 3350) developed and marketed by Laboratorio Dominguez in Argentina. It is an osmotic laxative used for the treatment of occasional or chronic constipation and for bowel cleansing (colon preparation) prior to diagnostic, endoscopic, or surgical procedures. The product line includes several formulations: Barex Unipeg (pure macrogol 3350), Barex 70 and Barex S (macrogol 3350 with electrolytes to maintain isotonic balance), Barex Plus (macrogol 3350 with electrolytes and ascorbic acid/sodium ascorbate), and Barex Kit (which combines macrogol 3350 with bisacodyl tablets). Macrogol 3350 is a high molecular weight polymer that is minimally absorbed from the gastrointestinal tract and acts physically by binding water molecules, increasing stool volume and softening feces to promote peristalsis.

Brand names
BarexBarex 70Barex70Barex-70Barex KitBarex PlusBarex SBarex Unipeg
Other names
PEG 3350PEG3350PEG-3350polyethylene glycol 3350

Beyond the preview

Go deeper on macrogol 3350.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on macrogol 3350.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call